In this episode, we speak with Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery at MilliporeSigma, the Global Science and Technology Group at Merck.
About Ashwini’s journey to her current role.
How to bridge the gaps between working groups with different skill sets for optimal computational drug discovery.
The interplay between AIDDISON™ and SYNTHIA™ to automate the drug discovery process.
The industry's critical requirements for progress in the AI drug discovery space.
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Podden och tillhörande omslagsbild på den här sidan tillhör
Murat Tunaboylu. Innehållet i podden är skapat av Murat Tunaboylu och inte av,
eller tillsammans med, Poddtoppen.
